Corona Remedies Boosts Production with Major Bhayla Plant Expansion Post-IPO Success

• Newly listed Corona Remedies announced significant capital expenditure for capacity expansion at its Bhayla manufacturing site in Gujarat.
• The move follows a highly successful IPO on December 15, 2025, which was subscribed 137 times and listed at a 38% premium.
• Expansion adds 240 million units, increasing annual tablet and capsule production capacity to 1.09 billion units from December 22, 2025.
• Funded by internal accruals, this aims to meet growing market demand and optimize production, maintaining high utilization rates.
• Corona Remedies, founded in 2004, specializes in branded formulations and operates WHO-GMP/EU GMP certified plants.

Why It Matters: Post-IPO, Corona Remedies expands Bhayla plant capacity to meet demand and boost production.